South America Insulin Delivery Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Insulin Delivery Devices Market Trends and Insights

Rising Diabetes Burden and Insulin-Treated Population

Diabetes prevalence is creating a broad and sustained demand base for the South America insulin delivery devices market. The International Diabetes Federation reported 35.4 million adults with diabetes in South and Central America, with the total projected to reach 52 million by 2050. The same source reported that 30.4% of adults with diabetes in the region, or 10.7 million people, remained undiagnosed.^{[1]International Diabetes Federation, “IDF Diabetes Atlas South and Central America Region,” IDF Diabetes Atlas, diabetesatlas.org} Brazil had 16.6 million adults with diabetes and an age-standardized prevalence of 10.6%, providing suppliers with a large base for pens, needles, and other insulin administration products. The growing use of long-acting insulin analogs in public care supports compatible pen delivery and recurring disposable supply demand. Brazil’s device registration requirements also favor suppliers with the quality documentation and approvals required for public and private distribution.

Expansion of Public Diabetes Programs and Pen Access

Public programs are shifting demand in the South American insulin delivery devices market beyond private purchasing. Brazil began a structured transition from NPH insulin to long-acting glargine across four pilot locations in February 2026, covering more than 50,000 patients in the initial phase. A Productive Development Partnership involving Biomm, Fiocruz, and Gan & Lee supported domestic glargine supply. Brazil’s Ministry of Health distributed 52,350 reusable injection pens across 16 states in July 2026 as part of the national rollout.^{[2]Ministério da Saúde do Brasil, “SUS Começa a Oferta Nacional de Insulina Glargina Para Crianças, Adolescentes e Idosos em Todo o País,” Ministério da Saúde, gov.br} Argentina’s coverage framework requires full coverage of insulin and related diabetes supplies through social insurance arrangements. Chile’s Ley Ricarte Soto provides pump hardware and monthly consumables for eligible people with Type 1 diabetes, reducing cost barriers for qualifying patients.

Shift From Syringes Toward Pen-Based Administration in Urban Care

Pen-based administration is expanding as patients and clinicians seek more convenient and accurate routine dosing. This trend is most visible in large urban areas, where private clinics and retail pharmacies offer broader access to branded insulin and delivery supplies. Brazil’s public distribution of reusable pens has provided many patients with their first practical experience using pen-based administration. The South American insulin delivery devices market also benefits from recurring demand for pen needles and replacement cartridges after initial device distribution. Brazil made items included in the Farmácia Popular program free of charge in February 2025, expanding access to listed diabetes medicines and supplies through pharmacies. Syringes will remain relevant in remote and lower-income settings but will likely have a more limited role where public programs supply pen-compatible insulin.

Connected Pens, Wearable Pumps, and Continuous Glucose Monitoring Integration

Connected delivery systems are gaining traction as glucose monitoring and insulin administration become increasingly integrated. Argentina’s 2025 diabetes supply update expanded coverage for new pump models, additional consumables, and intermittent glucose monitoring sensors. Chile added real-time continuous glucose monitoring to guarantee benefits for people under 18 with Type 1 diabetes and pregnant women with Type 1 diabetes in December 2025. Brazil evaluated real-time continuous glucose monitoring coverage for Type 1 diabetes through Consulta Pública 63/2026. These programs can create a clearer pathway for compatible pumps, smart pens, sensors, and software-supported follow-up. However, connected products carry a cost premium, and adoption depends on coverage decisions and clinician capacity. The South American insulin delivery devices market will likely see connectivity expand first through specialist care, pediatric programs, and patients with formal reimbursement.

High Out-of-Pocket Cost and Uneven Reimbursement

Household spending was a major constraint, where public coverage did not fully include advanced insulin delivery systems. In Chile, Ley Ricarte Soto covered pump hardware and recurring consumables for eligible individuals, subject to clinical criteria and administrative approval. A 2025 qualitative study identified cost, administrative complexity, and limited specialist availability outside metropolitan areas as key barriers to pump access. A 2024 systematic review reported a 64.6% treatment rate across South America, indicating that many diagnosed patients did not receive comprehensive treatment. The South American insulin delivery devices market served varied affordability segments, from basic syringes and standard pens to pumps and sensor-linked systems, while inconsistent enforcement and informal employment limited reimbursement access.

Currency Volatility and Import Dependence

Premium insulin pumps, smart pens, and continuous glucose monitoring-linked systems largely relied on imports, making the South American insulin delivery devices market vulnerable to currency fluctuations. In Argentina, peso depreciation increased distributor costs between procurement and sale, resulting in higher patient prices or lower margins. Brazil maintained significant insulin manufacturing capacity but relied on imported hardware for many pump and smart pen systems. Biomm and Fiocruz expanded domestic glargine production; however, these initiatives did not fully replace imported device hardware, while fixed local-currency tender prices reduced supplier interest in advanced products during rapid exchange-rate fluctuations.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Pens Lead Current Demand and Pumps Support Faster Growth

Insulin pens held 52.44% of the South America insulin delivery devices market share in 2025, supported by their broad use in Type 2 diabetes care, public procurement, and compatibility with pen-based insulin formulations. Disposable pens continue to support public tender volumes by simplifying distribution and administration. Reusable pens are gaining traction as Brazil distributes durable hardware alongside glargine cartridges. In July 2026, Brazil’s Ministry of Health distributed 52,350 reusable pens and more than 254,000 glargine cartridges across 16 states, supporting future demand for compatible needles, cartridges, patient education, and replacement supplies.

Insulin pumps are projected to grow at a CAGR of 9.35% from 2026 to 2031, making them the fastest-growing product category. Growth begins from a smaller base, as pump therapy requires clinical support, reimbursement, and a reliable supply of consumables. Patch pumps and automated hybrid closed-loop systems support growth by combining insulin administration with automated diabetes management. A real-world study of MiniMed 780G users in Argentina, Brazil, Colombia, and Chile reported that 78.1% of users achieved time-in-range targets above 70%. Syringes remain important in rural and cost-sensitive settings, while needle-free and jet injectors remain niche due to limited reimbursement support.

By Technology / Connectivity: Conventional Devices Lead While Connected Systems Expand

Non-connected devices held 71.34% of the South American insulin delivery devices market in 2025. Conventional pens, syringes, and pumps remain widely used because they are affordable and easier to include in standard procurement contracts. Public purchasers prioritize unit costs, while secondary cities often have limited digital health infrastructure and specialist support for data-driven insulin management. These factors sustain demand for conventional devices and recurring purchases of compatible consumables, even as advanced systems gain clinical acceptance.

Connected devices are projected to grow at a CAGR of 10.45% from 2026 to 2031. Bluetooth-enabled pens, sensor-linked pumps, and app-supported systems enable patients to record doses and share data with clinical teams. Argentina’s revised rules and Chile’s guaranteed monitoring coverage have improved access to connected care for selected patient groups. Brazil’s 2026 consultation on real-time continuous glucose monitoring could create an additional public access route for connected products. Adoption will continue to depend on reimbursement, training, and consistent access to sensors and consumables.

By Patient Age Group: Adults Provide Scale and Pediatrics Gains Policy Support

Adults aged 18 years and above held 66.24% of the South American insulin delivery devices market in 2025. The segment is large because Type 2 diabetes is concentrated among adults and older patients, with Brazil and Argentina providing a substantial patient base requiring routine insulin administration. Urban adults with private coverage are more likely to use premium connected devices, while public programs support demand through pen distribution and insulin supplies. Brazil’s glargine rollout includes people aged 70 years and above with Type 1 or Type 2 diabetes. Simple pen designs and patient training remain important for older users managing insulin at home.

Pediatrics is projected to grow at a CAGR of 10.67% from 2026 to 2031. The segment benefits from coverage programs that prioritize Type 1 diabetes management for children and adolescents. Chile’s GES Decree guarantees continuous glucose monitoring for children under 18 with Type 1 diabetes, while Argentina’s updated coverage rules support access to pump models and supplies for eligible patients. In July 2025, Medtronic received CE Mark approval for MiniMed 780G use in children as young as 2 years. Pediatric demand requires family education, clinical monitoring, and dependable access to supplies.

By Distribution Channel: Retail Pharmacies Lead and Online Pharmacies Gain Use

Retail pharmacies held 44.37% of the South American insulin delivery devices market in 2025. Their leadership is supported by direct patient access, pharmacy chains, and public dispensing programs. Brazil’s Farmácia Popular network provides a local route to obtain listed diabetes products and related supplies, and the program made all formulary items free of charge in February 2025. Retail pharmacies also support repeat purchases of pen needles, cartridges, and basic accessories, while hospital pharmacies remain important for device setup and patient education.

Online pharmacies are projected to grow at a CAGR of 12.53% from 2026 to 2031. Digital ordering simplifies repeat purchases and supports scheduled delivery of pen needles, sensors, and other consumables for urban patients. Growth is strongest where e-prescriptions are accepted, and patients are comfortable using digital health services. Online channels are particularly relevant for connected-device users, while diabetes clinics and dedicated centers remain important for advanced-device initiation. Argentina’s PRONADIA program is expanding integrated diabetes care in provincial capitals, supporting referrals and clinical follow-up.

By End User: Homecare Leads as Insulin Management Moves Outside Hospitals

Homecare settings held 43.67% of the South America insulin delivery devices market in 2025 and are projected to grow at a CAGR of 9.77% through 2031. This position reflects the shift of daily insulin management from hospitals to households. Brazil’s public system supports primary-care delivery, with patients continuing insulin administration at home after receiving treatment through basic health units. Pens simplify home administration and reduce clinical visits, while smart pens and connected pumps enable data sharing with care teams. This combination of convenience and clinical follow-up supports homecare demand.

Hospitals and specialty clinics continue to play a material role in pump initiation, inpatient insulin management, and structured patient training. These settings are particularly important for children, patients starting pump therapy, and individuals with complex treatment needs. Private networks in São Paulo support premium-device use through Type 1 diabetes centers, while ambulatory surgical centers remain a smaller category for pump starts and follow-up calibration. Argentina’s PRONADIA program supports decentralized diabetes care, extending specialist advice beyond major cities. Chile’s public monitoring coverage also supports device use at home following clinical assessment.

Geography Analysis

Brazil held 49.89% of the South American insulin delivery devices market share in 2025, supported by the scale of the Unified Health System, a large diabetic population, and established insulin production. The country had 16.6 million adults with diabetes and a 10.6% age-standardized prevalence. In April 2025, Novo Nordisk announced a BRL 6.4 billion 9USD 1.24 billion) investment to expand its Montes Claros facility, which supplies 12% of global insulin consumption to more than 70 countries. Biomm produced 10 million glargine units in 2025 and is targeting 20 million units by the end of 2026. Device regulations and public procurement processes continue to influence supplier access.

Argentina is projected to grow at an 11.56% CAGR from 2026 to 2031, driven by its 14% adult diabetes prevalence, the highest among South America’s large economies. Resolution 2091/2025 expanded mandatory coverage for pump models, consumables, and intermittent glucose monitoring sensors. Buenos Aires and Córdoba drive private demand for advanced devices, while provincial care programs can expand access across other cities. Colombia had 3.0 million adults with diabetes and an 8.4% prevalence, while Peru had an estimated 1.6 million adults with diabetes. Both countries offer stronger opportunities for pens and needles than premium connected systems.

Chile had 1.9 million adults with diabetes and a prevalence of 12.2%. Its smaller patient base is supported by reimbursement programs that facilitate access to pumps and monitoring devices for eligible patients. Chile’s GES coverage created a pathway for continuous glucose monitoring for qualifying people with Type 1 diabetes. Ecuador, Bolivia, Uruguay, Venezuela, Paraguay, and Suriname contribute primarily through basic syringes and pen needles. Peru’s healthcare infrastructure investment offers the clearest growth signal within this group.